Third Harmonic Bio Closes Upsized Initial Public Offering of Shares of Common Stock Trading on the NASDAQ Global Market
CFGI’s Life Sciences team assisted Third Harmonic Bio (NASDAQ: THRD) with their initial public offering.
Senti Biosciences Completes Merger With Dynamics Special Purpose Corp.
CFGI’s Capital Markets team assisted Senti Biosciences, Incorporated (“Senti Bio”) with the completion of its merger with Dynamics Special Purpose Corporation (“DYNS”) (Nasdaq: DYNS), a special purpose acquisition company.
BCP Raptor Holdco LP Completes Reverse Merger With Altus Midstream Company
CFGI’s Capital Markets team assisted privately-owned BCP Raptor Holdco LP (“BCP”), the parent company of EagleClaw Midstream, with the completion of an all-stock business combination with Altus Midstream Company (Nasdaq: ALTM) (“Altus”), creating a unique, fully-integrated midstream company.
2021 Year in Review
2021 was a year of tremendous change and growth for CFGI.
Capital Markets Advisory: 2021 Year in Review
2021 was an exciting year of growth for CFGI, which included a new partnership with CVC Capital Partners, one of the world’s largest private equity firms.
CFGI Celebrates Largest Promotion Class for 2022
2021 was an exciting year for CFGI; we announced a new partnership with CVC alongside current partner The Carlyle Group, saw significant growth in the business and can now announce the largest promotion class to date.
Enjoy Technology Completes Business Combination With Marquee Raine Acquisition Corp.
CFGI’s Capital Markets team assisted Enjoy Technology, Inc.
CFGI and Carlyle Partner with CVC Capital Partners
We’re excited to announce that CVC Capital Partners, one of the world’s largest private equity firms, will join forces with CFGI and The Carlyle Group to continue to propel the firm in our mission to be the world’s leading non-audit accounting and finance advisory firm.